Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients

Diabetes, Obesity and Metabolism

Volumn 14, Issue 9, 2012, Pages 852-858

  Pirags, V ^a   Lebovitz, H ^b   Fouqueray, P ^c  

^a PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^b Downstate Health Sciences University   (United States)

^c Poxel SA   (France)

Author keywords

Glycaemic control; Imeglimin; Insulin secretion; Metformin; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; IMEGLIMIN; METFORMIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; BRAIN HEMATOMA; BURNING SENSATION; CATHETER COMPLICATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FEVER; FLATULENCE; GLYCEMIC CONTROL; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERTENSION; INSECT STING; LABORATORY TEST; MALE; MEAL; MICROALBUMINURIA; MIDDLE EAR EFFUSION; MIGRAINE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PAPULAR RASH; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; POLYDIPSIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN ALLERGY; THROMBOPHLEBITIS; TONGUE HYPESTHESIA; TOOTH PAIN; TREMOR; UMBILICAL HERNIA; VITAL SIGN; VOMITING;

EID: 84864351659     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01611.x     Document Type: Article

References (20)

1. World Health Organisation Diabetes Fact Sheet No. 312. January 2011. Available from URL: Accessed 26 May 2011.
2. Ferrannini E. Insulin resistance versus insulin deficiency in noninsulin dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477-490.
3. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68: 2131-2162.
4. Campbell RK. Fate of the beta-cell in the pathophysiology of type 2 diabetes. J Am Pharm Assoc 2003; 49 (Suppl 1): S10-15.
5. Guillausseau PJ, Meas T, Virally M et al. Abnormalities in insulin secre- tion in type 2 diabetes mellitus. Diabetes Metab 2008; 34 (Suppl 2): S43-48.
6. Standl E. The importance of beta-cell management in type 2 diabetes. Int J Clin Pract Suppl 2007; 10-19.
7. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 81-86.
8. Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
9. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 361: 2545-2559.
10. Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 2010; 125: 328-361.
11. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
12. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010; 33: 501-506.
13. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12: 503-513.
14. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009; 11: 79-88.
15. Pourcet B, Fruchart JC, Staels B, Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 2006; 11: 379-401.
16. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007; 23: 945-952.
17. Salvatore T, Carbonara O, Cozzolino D, Torella R, Sasso FC. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors. Curr Diabetes Rev 2009; 5: 92-101.
18. Fouqueray P, Leverve X, Fontaine E et al. Imeglimin-a new oral anti-diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab 2011; 2: 126.
19. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits good glycemic control in type 2 diabetes mellitus patients. Presented at the 46th EASD Annual Meeting, Stockholm, Sweden, 2010.
20. Aschner P, Katzeff HL, Guo H et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-261.